Cell Source Stock Today
| CLCS Stock | USD 0.40 0.10 20.00% |
Performance5 of 100
| Odds Of DistressLess than 10
|
Cell Source is selling for under 0.4 as of the 19th of April 2024; that is -20 percent down since the beginning of the trading day. The stock's lowest day price was 0.4. Cell Source has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Cell Source are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 35.25 M outstanding shares. More on Cell Source
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cell Pink Sheet Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cell Source's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cell Source or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Itamar Shimrat |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Cell Source [CLCS] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cell Source's market, we take the total number of its shares issued and multiply it by Cell Source's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cell Source conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 35.25 M outstanding shares.
Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations.
Check Cell Source Probability Of Bankruptcy
Ownership AllocationCell Source retains a total of 35.25 Million outstanding shares. Cell Source retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Cell Ownership Details
Cell Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Cell Source jumping above the current price in 90 days from now is about 71.26%. The Cell Source probability density function shows the probability of Cell Source pink sheet to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the pink sheet has a beta coefficient of 4.7397 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cell Source will likely underperform. Additionally, cell Source has an alpha of 0.9642, implying that it can generate a 0.96 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Cell Source to move above the current price in 90 days from now is about 71.26 (This Cell Source probability density function shows the probability of Cell Pink Sheet to fall within a particular range of prices over 90 days) .
Cell Source Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cell Source market risk premium is the additional return an investor will receive from holding Cell Source long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cell Source. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cell Source's alpha and beta are two of the key measurements used to evaluate Cell Source's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 10.53 | |||
| Semi Deviation | 12.68 | |||
| Standard Deviation | 18.06 | |||
| Variance | 326.15 |
Cell Stock Against Markets
Picking the right benchmark for Cell Source pink sheet is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cell Source pink sheet price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cell Source is critical whether you are bullish or bearish towards Cell Source at a given time. Please also check how Cell Source's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cell Source without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
How to buy Cell Pink Sheet?
Before investing in Cell Source, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Cell Source. To buy Cell Source stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Cell Source. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Cell Source stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Cell Source stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Cell Source stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Cell Source, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Cell Source?
The danger of trading Cell Source is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cell Source is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cell Source. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cell Source is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cell Source. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Cell Source information on this page should be used as a complementary analysis to other Cell Source's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Cell Pink Sheet analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |